UWCCC Cancer Prevention and Control (CPC) Program Summary Co-Leaders: Hasan Mukhtar and Amy Trentham-Dietz PROJECT SUMMARY/ABSTRACT The Cancer Prevention & Control (CPC) Program spans basic, clinical, and population science to identify effective approaches to reduce the burden of cancer for patients, their families, and communities through improved prevention, early detection, and survival. In support of this overarching goal, the CPC program has defined three thematic aims. Theme 1: Identify promising chemopreventive targets and agents to test in clinical trials. Members build on a comprehensive integrated understanding of agents that decrease the incidence of cancer or its progression to clinically significant disease through drug development and clinical testing. Theme 2: Identify and implement effective approaches to reduce tobacco-related cancers. Members conduct intervention studies of innovative tobacco cessation approaches and lead observational cohort studies of real-world smoking patterns. Research focuses on underserved and minority populations since these are the same groups among whom the prevalence of smoking is greatest. Theme 3: Identify new strategies to improve the delivery of cancer care. Members identify effective approaches for delivering cancer screening and diagnostic tests and cancer therapies. CPC members are using innovative simulation modeling, bioinformatics, and multidisciplinary teams to improve the early detection of cancer; to leverage insights obtained through analysis of large databases to test approaches for improving access to guideline- concordant clinical care; and to incorporate patient-centered outcomes. CPC projects directly address the priorities present in the UWCCC catchment area and support reduction in cancer health disparities. The CPC Program has 33 members in 14 departments and 4 schools/colleges. Since 2012, CPC members have published 776 peer-reviewed manuscripts (25% intra-programmatic, 22% inter-programmatic). PIs were responsible for $11.1 million (direct costs) overall in peer-reviewed grant funding, with 60%, $6.7 million from NCI. Recent programmatic changes include new leadership, Dr. H. Mukhtar and Dr. A. Trentham-Dietz, and increased focus on interventions to reduce cancer and cancer risks in our communities. The CPC Program supports inter- and intra-programmatic interaction through pilot grants, seminars and retreats, a strong mentorship program, and collaborative working groups. Guided by strategic planning, priorities for the CPC program over the next 5 years include emphasizing cross-aim collaborations, building on existing momentum in health services research, and translational disparities research addressing needs in the UWCCC catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-44
Application #
9490024
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-30
Budget End
2019-03-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Bednarz, Bryan; Grudzinski, Joseph; Marsh, Ian et al. (2018) Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents. Health Phys 114:450-459
Romero-Masters, James C; Ohashi, Makoto; Djavadian, Reza et al. (2018) An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog 14:e1007221
Xu, Cheng; Chen, Feng; Valdovinos, Hector F et al. (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56-65
Wargowski, Ellen; Johnson, Laura E; Eickhoff, Jens C et al. (2018) Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer 6:21
Schrager, Sarina; Burnside, Elizabeth (2018) Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools. J Womens Health (Larchmt) :
van den Broek, Jeroen J; van Ravesteyn, Nicolien T; Mandelblatt, Jeanne S et al. (2018) Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making 38:140S-150S
Lu, Zhanping; Hong, Courtney C; Kong, Guangyao et al. (2018) Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. Cell Rep 22:1545-1559
Shea, Michael P; O'Leary, Kathleen A; Fakhraldeen, Saja A et al. (2018) Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ER?+ Mammary Carcinomas. Cancer Res 78:1672-1684
Carroll, Molly J; Fogg, Kaitlin C; Patel, Harin A et al. (2018) Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. Cancer Res 78:3560-3573
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121

Showing the most recent 10 out of 1528 publications